About Us
DrNose transforms early disease screening with a groundbreaking IoT-powered Electronic Nose. Unlike traditional diagnostic methods that rely on expensive gas chromatographs in labs, DrNose offers a real-time, low-cost, and non-invasive solution. This device analyses human breath using sensor-generated electronic patterns to detect cancers and chronic diseases.
Our technology is backed by two decades of R&D and combines up to eight specialised sensors with Intuitive AI algorithms to accurately diagnose diseases with small datasets, achieving robust and reliable results.
UP TO EIGHT SENSORS
Humans with certain diseases breathe out a variety of complex gaseous molecules. Dogs can smell these because their noses have around 300 million receptors in them. Humans are less sensitive but they too have around 6 million such receptors. DrNose is be able to diagnose multiple diseases using a combination of just up to eight sensors that generate a breath print to help determine what a person is suffering from.
INTUITIVE AI
Intuitive AI, developed by iOmniscient, enables accurate diagnostic patterns to be extracted from as few as 30 data points, unlike traditional AI, which requires massive datasets. This makes it ideal for clinical trials with limited data. The technology eliminates the need for deep learning or GPUs, allowing for quick, cost-effective training. By analysing data from the eight specialized sensors, it generates precise patterns to accurately diagnose various conditions as seen below.
Patterns generated by sensors in the DrNose device to determine the presence of a disease.
Mission
At DrNose, our mission is to make early disease screening for diagnostics accessible, portable, real-time, and non-intrusive. We empower individuals and healthcare providers to act quickly and bridge the gap between early diagnostics and better health outcomes.
90%+ accuracy across independent clinical trials
Ben Gurion University of the Negev, Israel
Conducted groundbreaking clinical trials for early detection of breast cancer.
University of New South Wales, Australia
Validated through clinical trials for early detection of lung cancer.
Patents
Out technology is safeguarded by international patents and trademarks across multiple jurisdictions, including the USA, Canada, and Australia. In addition, a new patent is currently in development to further secure our innovative solutions.
Key Partners
We are thankful to our key partners for their extended support in all our business endeavors.
We are about to be spun off from iOmniscient – a globally recognised leader in AI with over two decades of innovation. Our proven e-Nose technology has already been validated in industrial applications, laying the foundation for this groundbreaking medical device.
Our founding team blends extensive commercial experience with cutting-edge expertise in medicine, electronics, and AI. Together, we are redefining diagnostics with a commitment to innovation and commercial excellence.